WA43966: A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656 An Antisense Inhibitor of Complement Factor B in Patients with Primary IgA Nephropathy at High Risk of Progression

Brief description of study

The purpose of this study is to compare the safety and effects of RO7434656 versus placebo in participants with IgAN. In this study, you will get either RO7434656 or placebo. A placebo looks exactly like RO7434656 but has no active ingredients. RO7434656 is an experimental drug, which means health authorities, such as the United States (U.S) Food and Drug Administration (FDA) have not approved RO7434656 for the treatment of IgAN.

Clinical Study Identifier: s23-00705

ClinicalTrials.gov Identifier: NCT05797610

Principal Investigator: Naveed N. Masani.

Other Investigators: James Drakakis, Candace Grant.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies